JANX Q2 2024 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JANXJanux Therapeutics, Inc.

$852M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+741.7% YoY

Gross Profit

$8M94.3% margin

Operating Income

-$14M-155.4% margin

Net Income

-$6M-67.0% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+610.6%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$691M

Total Liabilities

$34M

Stockholders' Equity

$658M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$1M	+741.7%
Gross Profit	$8M	-$14M	+160.5%
Operating Income	-$14M	-$21M	+33.4%
Net Income	-$6M	-$18M	+66.0%